Lev Pharmaceuticals, Inc. Phase III Clinical Update Conference Call.NEW YORK -- Lev Pharmaceuticals, Inc. (OTCBB:LEVP) will host a live conference call and webcast today to discuss the results from its pivotal U.S. Phase III trial of C1 inhibitor, to be marketed as Cinryze[TM], for the prophylactic treatment of hereditary angioedema (HAE), also known as hereditary C1 inhibitor deficiency. DATE: September 11, 2007 TIME: 1PM EDT DIAL IN #: (800) 573-4840 INT'L #: (617) 224-4326 PASSCODE: 87790050 To access the live webcast, please click on the following link: http://phx.corporate-ir.net/playerlink.zhtml?c=130944&s=wm&e=1644636. A replay of this webcast will be available for 30 days. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at: www.streetevents.com, a password-protected event management site. About Lev Pharmaceuticals, Inc. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's C1 inhibitor, proposed to be marketed as Cinryze(TM), has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion